Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Fetal Medicine Foundation
To evaluate whether 400 mg daily oral micronized progesterone from 16 to 34 weeks' is effective in preventing recurrent spontaneous preterm birth (RSPB) and whether micronized progesterone use increases maternal serum progesterone levels.
Age
18–45
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
pregnant women less than 20 weeks' gestation who had at least one prior spontaneous preterm birth of a liveborn baby between 20 \& 0/7 weeks' and 36 \& 6/7 weeks' gestation.
You may not be if
multiple gestations, the presence of major fetal anomalies, progesterone use in the current pregnancy (ongoing or past), the presence of a cervical cerclage, and the presence of a placenta previa.
Clareo Health | Oral Progesterone for Prevention of Preterm Birth
